On Nov 01, major Wall Street analysts update their ratings for $Teladoc Health (TDOC.US)$, with price targets ranging from $9 to $14.
BofA Securities analyst Allen Lutz maintains with a hold rating, and adjusts the target price from $9.5 to $10.5.
Citi analyst Daniel Grosslight maintains with a hold rating, and adjusts the target price from $11.5 to $11.
Barclays analyst Stephanie Davis maintains with a buy rating, and adjusts the target price from $10 to $12.
Evercore analyst Elizabeth Anderson CFA maintains with a hold rating, and adjusts the target price from $9 to $10.
Oppenheimer analyst Michael Wiederhorn maintains with a buy rating, and adjusts the target price from $17 to $14.
Furthermore, according to the comprehensive report, the opinions of $Teladoc Health (TDOC.US)$'s main analysts recently are as follows:
The share price of Teladoc experienced an uplift of 12% following a Q3 performance that surpassed gloomy expectations. Analysts suggest investors consider acquiring shares amidst these developments.
The expectation for 2025 is a period of transition, with projections anticipating somewhat stable revenues for IC and persistent CAC dynamics throughout the year. This situation is likely to affect BH User growth and result in a decline in revenues compared to the previous year.
Here are the latest investment ratings and price targets for $Teladoc Health (TDOC.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
